Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2487191 | Journal of Pharmaceutical Sciences | 2009 | 10 Pages |
Abstract
The antisense oligonucleotide 2â²-O-methyl-RNA is a selective telomerase inhibitor targeting the telomerase RNA component and represents a potential candidate for anticancer therapy. The poor cellular uptake of 2â²-O-methyl-RNA is a limiting factor that may contribute to the lack of functional efficacy. To improve delivery of 2â²-O-methyl- RNA and consequently antitumoral efficiency in human lung cancer cells, we have investigated several transfection reagents. The transfection reagents DOTAP, Mega- Fectin 60, SuperFect, FuGENE 6 and MATra-A were tested for intracellular delivery. A FAM-labeled 2â²-O-methyl-RNA was used to assess the intracellular distribution by confocal laser scanning microscopy in A549 human non-small cell lung cancer cells. Telomerase activity was measured using the telomeric repeat amplification protocol. Cell viability after transfection was quantified by the MTT assay. All transfection reagents enhanced 2â²-O-methyl-RNA uptake in A549 cells but the cationic lipid reagents DOTAP and MegaFectin 60 were most efficient in the delivery of 2â²-O-methyl-RNA resulting in telomerase inhibition. Among both DOTAP exhibited the lowest cytotoxicity. Our experiments show that DOTAP is the most suitable transfection reagent for the delivery of 2â²-O-methyl-RNA in human lung cancer cells according to its relatively low cytotoxicity and its ability to promote efficient uptake leading to the inhibition of telomerase.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Julia Beisner, Meng Dong, Sebastian Taetz, Kamilla Piotrowska, Elke Kleideiter, Godehard Friedel, Ulrich Schaefer, Claus-Michael Lehr, Ulrich Klotz, Thomas E. Mürdter,